Jun 1, 2026 04:05PM
Jun 1, 2026 04:05PM
May 5, 2026 08:00AM
Apr 2, 2026 04:05PM
Apr 2, 2026 04:05PM
Mar 31, 2026 04:05PM
Mar 31, 2026 04:05PM Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Mar 12, 2026 06:39AM
Mar 11, 2026 07:00AM
Jan 26, 2026 07:00AM
Nov 19, 2025 08:32AM
Nov 19, 2025 08:30AM
Nov 5, 2025 07:30AM
Oct 21, 2025 08:00AM Minerva Neurosciences secures up to $200 million for schizophrenia drug trial
Oct 21, 2025 08:00AM
Aug 14, 2025 04:35PM
May 13, 2025 07:30AM
Feb 25, 2025 07:00AM
Nov 5, 2024 07:30AM
Aug 7, 2024 06:49AM
Aug 6, 2024 07:30AM Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
May 2, 2024 06:51AM
May 1, 2024 07:30AM
Feb 27, 2024 08:00AM
Feb 27, 2024 08:00AM
Feb 22, 2024 07:00AM
Nov 7, 2023 07:30AM
Aug 1, 2023 07:30AM Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Jun 28, 2023 08:31AM
Jun 28, 2023 08:30AM
May 15, 2023 07:30AM
May 10, 2023 08:00AM
May 10, 2023 08:00AM
May 1, 2023 07:03AM
May 1, 2023 07:01AM Minerva Neurosciences (NERV) Announces NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 1, 2023 07:00AM
May 1, 2023 07:00AM
Mar 8, 2023 07:30AM
Mar 8, 2023 07:30AM
Dec 28, 2022 08:01AM
Dec 28, 2022 08:00AM
Dec 28, 2022 08:00AM Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Nov 9, 2022 08:00AM
Nov 9, 2022 08:00AM
Oct 17, 2022 08:31AM
Oct 17, 2022 08:30AM
Oct 17, 2022 08:30AM
Sep 9, 2022 04:05PM
Sep 9, 2022 04:05PM Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
Aug 22, 2022 08:05AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All